Nuvation Bio Inc.(NUVB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,400 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
NUVB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Nuvation Bio Inc. (NUVB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NUVB at 29.5/100 on a 32-signal composite quality model, placing it at rank #2,400 of 2,879 stocks — the bottom half of the AI-ranked universe. NUVB scores in the top quartile across revenue growth (99.1). Areas of concern include profitability (6.0) and free cash flow (6.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Nuvation Bio Inc. reports quarterly revenue of $83.2M, net income of $5.4M, free cash flow of $5.1M. Top institutional holders of NUVB by reported 13-F value include FMR, Decheng Capital, BlackRock,, based on the most recent SEC filings. NUVB trades on the NYSE exchange and files with the SEC under CIK 1811063. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NUVB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nuvation Bio Inc. directly from SEC EDGAR. Nuvation Bio Inc.'s 13F Pro composite quality score has ranged between 7 and 70 since 2025, currently 29.5 — an improving long-term trajectory across 40 quarterly and live scoring snapshots.
Revenue
Q1 2026
$83.2M
Net Income
Q1 2026
$5.4M
Free Cash Flow
Q1 2026
$5.1M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+699.0% YoYNet Income
+64.0% YoYOperating Income
+64.0% YoYEPS (Diluted)
+71.6% YoYTotal Assets
+10.0% YoYTotal Debt
+742.5% YoYOp. Cash Flow
-33.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $62.9M +699.0% | $7.9M | $0.00 | — | — | — |
| Net Income | $-204.6M +64.0% | $-567.9M -9.5% | $-518.9M -398.0% | $-104.2M -20.0% | $-86.8M | — |
| Operating Income | $-213.1M +64.0% | $-592.6M -493.7% | $-99.8M +16.6% | $-119.7M -28.3% | $-93.3M | — |
| EPS (Diluted) | $-0.60 +71.6% | $-2.11 -502.9% | $-0.35 +27.1% | $-0.48 -9.1% | $-0.44 | — |
| Total Assets | $594.8M +10.0% | $540.6M -13.0% | $621.5M -7.5% | $672.1M -13.4% | $776.2M | — |
| Total Debt | $52.9M +742.5% | $6.3M | $0.00 | — | — | — |
| Operating Cash Flow | $-173.4M -33.0% | $-130.4M -91.8% | $-68.0M +29.2% | $-96.1M -40.9% | $-68.2M | — |
Get alerted when NUVB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Nuvation Bio Inc. including:
Top Institutional Holders of NUVB
FMR LLC
$223.0M51,989,593 shDecheng Capital LLC
$111.3M25,954,439 shBlackRock, Inc.
$107.7M25,100,374 shVANGUARD CAPITAL MANAGEMENT LLC
$49.9M11,626,198 shOmega Fund Management, LLC
$34.7M8,081,089 shLaurion Capital Management LP
$33.6M7,822,638 shSTATE STREET CORP
$29.1M6,784,927 shGEODE CAPITAL MANAGEMENT, LLC
$25.2M5,863,654 shBANK OF AMERICA CORP /DE/
$13.8M3,219,826 shRedmile Group, LLC
$13.5M3,153,256 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $223.0M | 51,989,593 |
| Decheng Capital LLC | $111.3M | 25,954,439 |
| BlackRock, Inc. | $107.7M | 25,100,374 |
| VANGUARD CAPITAL MANAGEMENT LLC | $49.9M | 11,626,198 |
| Omega Fund Management, LLC | $34.7M | 8,081,089 |
| Laurion Capital Management LP | $33.6M | 7,822,638 |
| STATE STREET CORP | $29.1M | 6,784,927 |
| GEODE CAPITAL MANAGEMENT, LLC | $25.2M | 5,863,654 |
| BANK OF AMERICA CORP /DE/ | $13.8M | 3,219,826 |
| Redmile Group, LLC | $13.5M | 3,153,256 |
More Healthcare Companies
View all Healthcare →Put NUVB on your watchlist
Track score changes the day Nuvation Bio Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NUVB a good stock to buy?
13F Pro's AI-powered analysis of Nuvation Bio Inc. (NUVB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NUVB are available on the NUVB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own NUVB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NUVB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Nuvation Bio Inc.'s investment landscape.